PDCD1 and hepatocellular carcinoma: Both nivolumab and pembrolizumab, the anti-PD-1 monoclonal antibody, were approved as second-line treatments for advanced HCC by Food and Drug Administration (FDA) based on Checkmate 040 (8) and Keynote 224 Trials (9).